Local 12: Study: Targeted drug therapy slows progression of certain brain tumors
Drug could reduce the need for chemotherapy, radiation and surgery, UC expert says
New research out of the University of Cincinnati shows a targeted drug therapy had positive results in delaying the progression of a specific form of glioma, which is a slow-growing brain tumor.
UC Cancer Center brain tumor specialists said it appears to be an option for treatment and would delay radiation and chemotherapy. Local 12 interviewed Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine who said this drug is given after surgery to remove this kind of tumor and appears to be a powerful player in reducing new growth.
"This new drug Vorasidenib is an IDH1, IDH2 inhibitor. And what it does, it actually inhibits these receptors that are found, or proteins that are found on the tumors,” Chaudhary said.
Researchers studied 331 people with this disease and compared the study drug to a placebo. Those given the targeted therapy did not have disease progression for more than 27.7 months. For those in the placebo group, it was only 11.1 months.
"Whether this is going to pan out to be a survival benefit in the long run, we don't know. But imagine being 30 years old and not having to go through chemo, radiation, further surgery and just be on this drug for almost three years now, and hopefully longer, is a great benefit to these patients, where we've never had a victory before,” Chaudhary told Local 12.
This targeted treatment was so effective that the patients in the original placebo group whose cancer progressed during the study were switched to the drug. It gives promising new hope.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
The Verge: The teens making friends with AI chatbots
May 9, 2024
Kelly Merrill, an assistant professor of health communications and technology in the University of Cincinnati's College of Arts and Sciences, was cited in an article on teen use of AI chatbots for friendship and therapy purposes. Merrill, who studies the mental and social health benefits of communication technologies, told The Verge that extensive research has been conducted on AI chatbots that provide mental health support, and the results are largely positive.
TVNewsCheck: A new documentary traces the popularity of local TV news to one man, Al Primo
May 9, 2024
A documentary by UC journalism professor Brian Calfano received kudos by the broadcasting trade publication TVNewsCheck. The documentary follows the career of Al Primo (1935-2022), an American television news executive who is credited with creating the Eyewitness News format.
Local 12: UC investigates potential PFAS contamination in groundwater
May 9, 2024
Local news media highlight UC project to study contamination in groundwater in southwest Ohio.